TAP’s Prevacid PAP Is Available To Part D Beneficiaries; Bristol-Myers Squibb To Focus On Coalition Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
TAP extended its Prevacid prescription assistant program to Medicare drug plan enrollees whose household income is between 135% and 200% of the federal poverty level.
You may also be interested in...
Enbrel Growth Plans Include Copay Assistance, DTC
Market share has stabilized but Amgen acknowledges that the TNF inhibitor “isn’t performing up to our expectations.”
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.